|
|
||||||||
J Thorac Cardiovasc Surg 2002;123:391-392
© 2002 The American Association for Thoracic Surgery
Brief Communications |
From the Departments of Surgerya and Pathology,b Teikyo School of Medicine, Tokyo, Japan.
Received for publication July 20, 2001. Accepted for publication Sept 28, 2001. Address for reprints: Iwao Takanami, MD, Department of Surgery, Teikyo School of Medicine, 2-11 Kaga 2-Chome, Itabashi-Ku, Tokyo, 173 Japan (E-mail: takanami{at}med.teikyo-u.ac.jp).
|
Patients and methods
Two patients, 1 woman and 1 man, 32 and 16 years of age, with Askin tumor were treated in our institute between 1990 and 2001(Table 1). The clinical and morphologic findings with immunohistochemical staining
3 involving HBA-71 support the diagnosis of Askin tumor in these patients. At the time of the initial diagnosis, neither of the patients had metastases. We performed chest wall resections involving the ribs in both patients, and both subsequently received chemotherapy. Their chemotherapeutic regimens consisted of cyclophosphamide, doxorubicin (Adriamycin), vincristine, and dactinomycin (actinomycin D).
|
|
Askin tumor may present as a chest wall mass with thoracopulmonary symptoms such as chest pain, cough, or dyspnea. In our patient 1 a posterior pleural mass was discovered during routine radiographic screening without symptoms, whereas patient 2 had an expanding mass in the chest wall accompanied by pain. Removal was possible in both patients. In patient 1, complete removal of the tumor with chest wall resection involving 4 ribs, followed by chemotherapy, was possible. In patient 2, complete removal may not have been achieved during the first operation. Askin tumor has a predilection to reappear in approximately the same area as the primary neoplasm.
1 Metastases to the pleura, rib, pericardium, diaphragm, and vertebra/spinal cord were easily detected by computed tomographic scanning and magnetic resonance imaging in patient 2. Even though we performed relatively wide excisions of the local Askin tumor recurrences followed by chemotherapy and radiotherapy, tumors continued to appear at sites adjacent to the excised tumor, and Askin tumor recurred locally 6 times in 7 years.
The prognosis in Askin tumor is very poor despite the combination of chemotherapy, radiotherapy, and surgical removal, with a 2-year survival of 38% and a 6-year survival of only 14%.
2 Very few cases have been reported in which the patient is still alive. Our patients received aggressive combined therapy, and the outcome was more favorable than that reported in the literature. From our preliminary data, we suggest that Askin tumor should be treated with complete surgical excision followed by an aggressive chemotherapy regimen. For local recurrences, postoperative chemotherapy and radiotherapy after complete excision help to prolong survival. A multimodal therapy consisting of surgical resection, appropriate chemotherapy, and radiotherapy seems to be of some benefit in treating Askin tumor, and even in treating recurrences.
References
This article has been cited by other articles:
![]() |
G. Veronesi, L. Spaggiari, T. De Pas, P. G. Solli, F. De Braud, G. P. Catalano, G. Curigliano, F. Leo, and U. Pastorino Preoperative chemotherapy is essential for conservative surgery of Askin tumors J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 428 - 429. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |